Kyverna Therapeutics, Inc.

NasdaqGS:KYTX Stock Report

Market Cap: US$602.5m

Kyverna Therapeutics Future Growth

Future criteria checks 2/6

Kyverna Therapeutics's earnings are forecast to decline at 6.6% per annum while its annual revenue is expected to grow at 64.2% per year. EPS is expected to grow by 6.5% per annum. Return on equity is forecast to be -147.1% in 3 years.

Key information

-6.6%

Earnings growth rate

6.49%

EPS growth rate

Biotechs earnings growth25.3%
Revenue growth rate64.2%
Future return on equity-147.11%
Analyst coverage

Low

Last updated03 Jun 2026

Recent future growth updates

Recent updates

Seeking Alpha • Apr 21

Kyverna Therapeutics Positive Phase 2 Readout: Deep Responses, But Very Small Sample

Summary Kyverna Therapeutics (KYTX) reported robust early Phase 2 miv-cel data in gMG, showing 100% response rates and deep, durable clinical improvements. KYTX’s miv-cel offers rapid onset, potential for treatment-free remission, and a differentiated safety profile, but results are based on a small, uncontrolled cohort. The market discounts KYTX due to execution risk, small sample size, and anticipated dilution, despite a modest $350M enterprise value and $279M cash runway. If Phase 3 validates these findings, miv-cel could redefine gMG treatment and expand into a multi-indication autoimmune platform, positioning today’s valuation as an early entry. Read the full article on Seeking Alpha
Analysis Article • Nov 03

We're Keeping An Eye On Kyverna Therapeutics' (NASDAQ:KYTX) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Mar 21

Kyverna: 2 Myasthenia Gravis Program Catalysts On Deck In 2025

Summary Interim data from phase 2 KYSA-6 study, using KYV-101 for the treatment of patients with Myasthenia Gravis, expected 2nd half of 2025. The global Myasthenia Gravis market is expected to generate sales of $6.7 billion by 2032. Release of topline data from phase 2 KYSA-8 study, using KYV-101 for the treatment of patients with Stiff Person Syndrome, expected in 1st half of 2026. The company is developing differentiated CD-19 CAR-T with a fully-human construct to reduce safety incidents of CRS and ICANS for starters; Plus, incorporate greater B-cell depletion and immune reset. Read the full article on Seeking Alpha
Seeking Alpha • Dec 12

Kyverna Therapeutics: CAR T-Cells Trying To Impact Inflammatory Disorders

Summary Kyverna Therapeutics is pioneering engineered cell therapy for inflammatory disorders, leveraging CAR-T cell therapy's success in B-cell cancers. KYTX holds $104.7M in cash and $216.9M in marketable securities, with a quarterly net loss of $34.5M. The company has a cash runway of 9-10 quarters but faces high cash burn and potential dilution risks in the not-too-distant future. Investors should hold off for now as the programs and the field at large matures. Read the full article on Seeking Alpha
Analysis Article • Nov 17

Here's Why We're Watching Kyverna Therapeutics' (NASDAQ:KYTX) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Aug 08

We're Not Very Worried About Kyverna Therapeutics' (NASDAQ:KYTX) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Earnings and Revenue Growth Forecasts

NasdaqGS:KYTX - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202853-279N/A-3333
12/31/202718-215-170-1925
12/31/2026N/A-178-145-1554
3/31/2026N/A-156-152-150N/A
12/31/2025N/A-161-155-154N/A
9/30/2025N/A-161-158-157N/A
6/30/2025N/A-159-142-141N/A
3/31/2025N/A-145-135-134N/A
12/31/2024N/A-127-116-114N/A
9/30/2024N/A-111-98-96N/A
3/31/2024N/A-76-68-66N/A
12/31/2023N/A-60-53-52N/A
9/30/20230-48-43-43N/A
12/31/20227-29-37-36N/A
12/31/20216-26-23-22N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: KYTX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: KYTX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: KYTX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: KYTX's revenue (64.2% per year) is forecast to grow faster than the US market (12.8% per year).

High Growth Revenue: KYTX's revenue (64.2% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: KYTX is forecast to be unprofitable in 3 years.

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/09 21:49
End of Day Share Price 2026/07/09 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Kyverna Therapeutics, Inc. is covered by 6 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mitchell KapoorH.C. Wainwright & Co.
Lut Ming ChengJ.P. Morgan
Thomas SmithLeerink Partners LLC